A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
Dr Anne Mortimer
Director of Planning (Enterprise & London)
T: 020 7679 4882
As Director of Planning (Enterprise & London), Anne is responsible for managing strategic projects, developing new enterprise policies, and developing and reporting metrics on behalf of the Vice-Provost.
Anne has a DPhil in synthetic organic chemistry and 10 years of research experience at the University of Oxford, University of Würzburg and in the Department of Chemistry at UCL.